A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants

  • Hitt Sharma*
  • , Sameer Parekh
  • , Pramod Pujari
  • , Sunil Shewale
  • , Shivani Desai
  • , Anand Kawade
  • , Sanjay Lalwani
  • , M. D. Ravi
  • , Veena Kamath
  • , Jagannath Mahopatra
  • , Ganesh Kulkarni
  • , Deepak Tayade
  • , Padmasani Venkat Ramanan
  • , Kheya Ghosh Uttam
  • , Lalit Rawal
  • , Avinash Gawande
  • , N. Ravi Kumar
  • , Nishikant Tiple
  • , Jayant Vagha
  • , Pareshkumar Thakkar
    • Prashant Khandgave, Bhaskar Jedhe Deshmukh, Anurag Agarwal, Vikas Dogar, Manish Gautam, K. S. Jaganathan, Rakesh Kumar, Inderjit Sharma, Sunil Gairola
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology